United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

7:00am BST
Change (% chg)

¥10 (+0.59%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4503.T


Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)


Beta: 0.58
Market Cap(Mil.): ¥3,643,192.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 1.89


  4503.T Industry Sector
P/E (TTM): 18.89 37.20 37.97
EPS (TTM): 89.55 -- --
ROI: 14.04 15.00 14.27
ROE: 15.03 16.08 15.48

BRIEF-Xcelra enters into drug collaboration with Astellas Pharma

* Xcelra enters into a drug repurposing collaboration with Astellas Pharma

07 Jun 2016

BRIEF-Astellas, Seattle Genetics present clinical data in metastatic urothelial cancer

June 6 Astellas Pharma Inc and Seattle Genetics Inc :

06 Jun 2016

BRIEF-Medivation and Astellas initiate Phase III trial of enzalutamide

* Astellas and Medivation initiate Phase III trial of enzalutamide in patients with triple-negative breast cancer

02 Jun 2016

BRIEF-Boya Bio-Pharmaceutical plans to invest 150 mln yuan to set up buyout fund with partners

* Says it plans to invest 150 million yuan ($22.99 million) to set up buyout fund in medical industry with partners

16 May 2016

BRIEF-Astellas Pharma to retire 68 mln treasury shares

* Says it will retire 68 million shares (3.1 percent stake) of its common stock on June 20

11 May 2016

BRIEF-Astellas to retire treasury stock equivalent to 3.06 pct of shares outstanding

* to retire treasury stock equivalent to 3.06 percent of shares outstanding on June 20 Further company coverage:

11 May 2016

BRIEF-Astellas Pharma names Rodrigo Fernandez executive director, international business

* Astellas names Rodrigo Fernandez executive director, international business Source text for Eikon: Further company coverage:

28 Apr 2016

UBS, MPM team up on $471 million cancer fund to speed drug development

(Corrects minimum commitment to $200,000 from $500,000 figure given by UBS on Wednesday)

28 Apr 2016

OFFICIAL CORRECTION-UBS, MPM team up on $471 mln cancer fund to speed drug development

ZURICH, April 27 A $471 million UBS venture fund aims to generate annual returns "north of 10 percent" for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights.

28 Apr 2016

UPDATE 1-U.S. lawmakers want health agencies to lower prostate cancer drug cost

March 28 A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi.

29 Mar 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.